Literature DB >> 21357294

Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Gabriel Cabot1, Alain A Ocampo-Sosa, Fe Tubau, María D Macia, Cristina Rodríguez, Bartolomé Moya, Laura Zamorano, Cristina Suárez, Carmen Peña, Luis Martínez-Martínez, Antonio Oliver.   

Abstract

The prevalence and impact of the overexpression of AmpC and efflux pumps were evaluated with a collection of 190 Pseudomonas aeruginosa isolates recovered from bloodstream infections in a 2008 multicenter study (10 hospitals) in Spain. The MICs of a panel of 13 antipseudomonal agents were determined by microdilution, and the expressions of ampC, mexB, mexY, mexD, and mexF were determined by real-time reverse transcription (RT)-PCR. Up to 39% of the isolates overexpressed at least one of the mechanisms. ampC overexpression (24.2%) was the most prevalent mechanism, followed by mexY (13.2%), mexB (12.6%), mexF (4.2%), and mexD (2.2%). The overexpression of mexB plus mexY, documented for 5.3% of the isolates, was the only combination showing a significantly (P=0.02) higher prevalence than expected from the frequencies of the individual mechanisms (1.6%). Additionally, all imipenem-resistant isolates studied (25 representative isolates) showed inactivating mutations in oprD. Most of the isolates nonsusceptible to piperacillin-tazobactam (96%) and ceftazidime (84%) overexpressed ampC, while mexB (25%) and mexY (29%) overexpressions gained relevance among cefepime-nonsusceptible isolates. Nevertheless, the prevalence of mexY overexpression was highest among tobramycin-nonsusceptible isolates (37%), and that of mexB was highest among meropenem-nonsusceptible isolates (33%). Regarding ciprofloxacin-resistant isolates, besides the expected increased prevalence of efflux pump overexpression, a highly significant link to ampC overexpression was documented for the first time: up to 52% of ciprofloxacin-nonsusceptible isolates overexpressed ampC, sharply contrasting with the 24% documented for the complete collection (P<0.001). In summary, mutation-driven resistance was frequent in P. aeruginosa isolates from bloodstream infections, whereas metallo-β-lactamases, detected in 2 isolates (1%) producing VIM-2, although with increasing prevalences, were still uncommon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357294      PMCID: PMC3088238          DOI: 10.1128/AAC.01645-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Mutation and evolution of antibiotic resistance: antibiotics as promoters of antibiotic resistance?

Authors:  Jesus Blázquez; Antonio Oliver; José-María Gómez-Gómez
Journal:  Curr Drug Targets       Date:  2002-08       Impact factor: 3.465

2.  Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains.

Authors:  Herin Oh; Jonas Stenhoff; Shah Jalal; Bengt Wretlind
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

3.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

4.  Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides.

Authors:  J R Aires; T Köhler; H Nikaido; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000).

Authors:  Teresa M Coque; Antonio Oliver; José Claudio Pérez-Díaz; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli.

Authors:  Antonio Oliver; Linda M Weigel; J Kamile Rasheed; John E McGowan; Patti Raney; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  Maria Tomás; Michel Doumith; Marina Warner; Jane F Turton; Alejandro Beceiro; German Bou; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

8.  [Molecular characterization of Pseudomonas aeruginosa isolates in Cantabria, Spain, producing VIM-2 metallo-beta-lactamase].

Authors:  María-Cruz Rodríguez; Belén Ruiz del Castillo; Cristina Rodríguez-Mirones; María Romo; Idoia Monteagudo; Luis Martínez-Martínez
Journal:  Enferm Infecc Microbiol Clin       Date:  2009-05-01       Impact factor: 1.731

Review 9.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals.

Authors:  Kyungwon Lee; Wee Gyo Lee; Young Uh; Gyoung Yim Ha; Jihyun Cho; Yunsop Chong
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  71 in total

1.  Changes in ciprofloxacin resistance levels in Enterobacter aerogenes isolates associated with variable expression of the aac(6')-Ib-cr gene.

Authors:  Elena Ruiz; Alain A Ocampo-Sosa; Julia Alcoba-Flórez; Elena Román; Guillaume Arlet; Carmen Torres; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

2.  Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.

Authors:  Gabriel Cabot; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Alfonso Navas; Jesús Blázquez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

3.  A convenient method to screen for carbapenemase-producing Pseudomonas aeruginosa.

Authors:  Damien Fournier; Pauline Garnier; Katy Jeannot; Amélie Mille; Anne-Sophie Gomez; Patrick Plésiat
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

4.  Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.

Authors:  Xavier Mulet; Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

5.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 6.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 7.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

8.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

10.  Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.

Authors:  Yu Mi Wi; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Kwan Soo Ko; Kyong Ran Peck; Jae-Hoon Song; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.